The COVID-19 pandemic has highlighted the crucial importance of supply chain resilience, especially in pharmaceutical companies. The disruptions exposed vulnerabilities compounded by the industry's globalized and complex nature. In Vietnam, the pharmaceutical sector is vital, serving approximately 97.33 million people. Despite significant growth, the industry faces challenges like heavy reliance on imported drugs, which make up nearly half of total consumption. The pandemic further strained supply chains, causing shortages and price hikes due to demand spikes and logistical issues.
This study explores the perceptions of Vietnamese pharmaceutical companies regarding their supply chain capabilities and competencies and their impact on resilience. Using a survey methodology, data was collected from 109 pharmaceutical companies in Vietnam through convenience sampling, considering company size, ownership, and types. The analysis involved descriptive statistics, Cronbach’s Alpha reliability testing, and multiple regression analysis.
Finding reveal that "Information System Capabilities (ISC)" and "Supply Chain Management Strategies (SMS)" significantly and positively influence both the agility and robustness of supply chains. "Risk Management Capabilities (RMC)" positively and significantly affect robustness alone. The study emphasizes the need for strategic investments in technology and risk management to enhance supply chain resilience, allowing companies to effectively handle uncertainties and disruptions while maintaining operational excellence.
